{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:09:45Z","timestamp":1772892585985,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,15]]},"DOI":"10.1097\/tp.0b013e3182911739","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T13:54:16Z","timestamp":1367502856000},"page":"1331-1337","source":"Crossref","is-referenced-by-count":41,"title":["Proteasome Inhibition Profoundly Affects Activated Human B Cells"],"prefix":"10.1097","volume":"95","author":[{"given":"Arend","family":"Mulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Heidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Vergunst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave L.","family":"Roelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans H.J.","family":"Claas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/TP.0b013e3182483713","article-title":"A personal perspective: 100-year history of the humoral theory of transplantation.","volume":"93","author":"Terasaki","year":"2012","journal-title":"Transplantation"},{"key":"R3-6-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMcibr041505","article-title":"Death, destruction, and the proteasome.","volume":"351","author":"Tansey","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.cdd.4402297","article-title":"Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.","volume":"15","author":"Maseda","year":"2008","journal-title":"Cell Death Differ"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition.","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.transproceed.2008.10.073","article-title":"Proteasome inhibition reduces donor-specific antibody levels.","volume":"41","author":"Everly","year":"2009","journal-title":"Transplant Proc"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/TP.0b013e3181dde912","article-title":"Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.","volume":"90","author":"Trivedi","year":"2010","journal-title":"Transplantation"},{"key":"R16-6-20210129","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.4049\/jimmunol.177.11.7715","article-title":"B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection.","volume":"177","author":"Noorchashm","year":"2006","journal-title":"J Immunol"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1111\/j.1600-6143.2010.03223.x","article-title":"B cells help alloreactive T cells differentiate into memory T cells.","volume":"10","author":"Ng","year":"2010","journal-title":"Am J Transplant"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.coi.2008.03.003","article-title":"Cytokine-producing B lymphocyteskey regulators of immunity.","volume":"20","author":"Lund","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/j.1600-6143.2011.03773.x","article-title":"Matchmaking the B-cell signature of tolerance to regulatory B cells.","volume":"11","author":"Chong","year":"2011","journal-title":"Am J Transplant"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/TP.0b013e3181874a36","article-title":"Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.","volume":"86","author":"Heidt","year":"2008","journal-title":"Transplantation"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/11.5.813","article-title":"Differential regulation of transcription termination occurring at two different sites on the micro-delta gene complex.","volume":"11","author":"Kim","year":"1999","journal-title":"Int Immunol"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in vivo.","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-6143.2011.03833.x","article-title":"In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.","volume":"12","author":"Kamburova","year":"2012","journal-title":"Am J Transplant"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.","volume":"22","author":"Papandreou","year":"2004","journal-title":"J Clin Oncol"},{"key":"R25-6-20210129","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/j.1600-6143.2012.04126.x","article-title":"Bortezomib for acute antibody-mediated rejection in liver transplantation.","volume":"12","author":"Paterno","year":"2012","journal-title":"Am J Transplant"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-6143.2009.02968.x","article-title":"Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.","volume":"10","author":"Sberro-Soussan","year":"2010","journal-title":"Am J Transplant"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1600-6143.2011.03982.x","article-title":"A novel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals.","volume":"12","author":"Heidt","year":"2012","journal-title":"Am J Transplant"},{"key":"R28-6-20210129","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells.","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2249.2001.01497.x","article-title":"Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals.","volume":"124","author":"Mulder","year":"2001","journal-title":"Clin Exp Immunol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e3182911739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:32:33Z","timestamp":1620977553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201306150-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,15]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3182911739","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,15]]}}}